NUVA stock has been down today on rumors that JNJ (Johnson & Johnson) will announce a lateral fusion device in the post earnings conference call. JNJ web site shows that the head of its device business will be on the call indicating there may be some truth to the rumor.
NuVasive’s main business is lateral fusion devices.
If there is no competing device on JNJ call, NUVA is a short term buy, otherwise it is short. The early bird catches the worm; consider listening to the call and immediately entering the position
